Also trades as: CYYNF (OTC) · $vol 0M
CYP.AX ASX
Cynata Therapeutics Limited
1W: +0.0%
1M: +0.0%
3M: -21.4%
YTD: -97.1%
1Y: -94.9%
3Y: -91.5%
5Y: -98.1%
A$0.01 ($0.01)
-0.00 (-0.00%)
Weekly Expected Move ±3.4%
A$0
A$0
A$0
A$0
A$0
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$2M
-9.2% ▼
5Y CAGR: +2.1%
Gross Profit
-$260K
-113.8% ▼
Operating Income
-$10M
-19.2% ▼
Net Income
-$9M
+3.2% ▲
EPS (Diluted)
$-0.04
+16.2% ▲
EBITDA
-$8M
+19.0% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $8M | $2M | $2M | $2M | $2M |
| YoY Growth | +402.6% | -78.7% | +40.0% | -18.6% | -9.2% |
| Cost of Revenue | $280K | $280K | $281K | $0 | $260K |
| Gross Profit | $7M | $1M | $2M | $2M | -$260K |
| Gross Margin | 96.4% | 83.1% | 100.0% | 100.0% | -15.2% |
| R&D Expenses | $9M | $12M | $9M | $8M | $5M |
| SG&A Expenses | $4M | $3M | $4M | $2M | $4M |
| Operating Expenses | $12M | $16M | $11M | $10M | $9M |
| Operating Income | -$7M | -$17M | -$9M | -$8M | -$10M |
| Operating Margin | -88.8% | -1000.0% | -380.4% | -430.9% | -565.8% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$6M | -$16M | -$12M | -$9M | -$11M |
| Tax Expense | -$833K | -$2M | -$2M | -$2M | -$2M |
| Net Income | -$5M | -$14M | -$10M | -$9M | -$9M |
| Net Margin | -70.1% | -863.0% | -420.8% | -498.1% | -531.0% |
| EPS (Diluted) | $-0.04 | $-0.10 | $-0.05 | $-0.05 | $-0.04 |
| EBITDA | -$6M | -$16M | -$10M | -$9M | -$8M |
| Shares Outstanding | 143M | 145M | 180M | 205M | 237M |